CClinicalTrials.gg
Not yet recruitingNCT06174714Indo-SURFTUpdated Jul 11, 2024

Effectiveness of Indo-SURFT in Reducing Addictive Substance Use in Women With Substance Use Disorders

An interventional study of Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT) in Substance Use Disorders, sponsored by Indonesia University. Not yet recruiting. Open to female participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by Indonesia University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
Female
01

Study summary

Relapse in women was associated with depression, interpersonal stress, and relationship conflict with others when compared with men. The differences in gender profiles with substance use disorders (SUD) leads to the need for management strategies that are sensitive to each gender. This is a challenge to build a new module that can be applied continuously by collaborating CBT and several other psychosocial interventions, such as motivational enhancement therapy. The investigators compiled Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT). By implementing this module, it is hoped that it can provide short and long term effects and reduce the relapse rate in women with SUD.

02

Conditions studied

  • Substance Use Disorders
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

This study's planned enrollment of 30 is below the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

Indonesia University is the lead sponsor of 448 studies on the registry; 56 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • women aged 18-59 years old
  • diagnosed with substance use disorders based on DSM-V or ICD-10

Exclusion criteria

Exclusion Criteria:

  • subjects with severe mental disorder or intellectual disability
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    MI and Indo-SURFT

    once a week motivational interviewing/motivational enhancement therapy (MI) for 4 weeks, followed by once a week CBT using Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT) for 8 weeks.

    Behavioral: Indonesia Substance Use Reduction for Female Therapy (Indo-SURFT)

Interventions

  • BehavioralIndonesia Substance Use Reduction for Female Therapy (Indo-SURFT)

    4 weeks of motivational interviewing/motivational enhancement therapy (MI) followed by 8 weeks cognitive behavioral therapy (CBT) using Indo-SURFT module.

06

What researchers measure

Primary outcomes

  1. Abstinence from Substance Use

    Timeline Follow Back (TLFB): to assess daily use of addictive substances by writing yes/no for 28 days. This data will be collected weekly retrospectively to reduce the risk of recall bias.

    Time frame: post-intervention (week 13)

  2. Decrease in Addiction Severity

    Addiction Severity Index (ASI), Indonesia version, measuring several domains: 1) Medical health (n= 11), 2) Employment/ support status (n= 24), 3 \& 4) Drug/ alcohol use (n= 35), 5) Illegal activity/ legal status (n= 32), 6) Family/ social relationships (n= 38) and 7) Psychiatric health (n= 23). Lesser score indicates better outcome.

    Time frame: pre-intervention (week 0), and post-intervention (week 13)

  3. Improvement in Motivation to Change

    University of Rhode Island Change Assessment (URICA), measuring motivation to change with 4 domains: 1) pre-contemplation, 2) contemplation, 3) action, and 4) maintenance. A higher score indicates a better outcome.

    Time frame: pre-intervention (week 0), and post-intervention (week 13)

  4. Improvement in Substance Craving

    Visual Analog Scale (VAS), measuring substance craving severity. Range 0 (no craving) - 100 (severe craving). A lower score indicates a better outcome.

    Time frame: pre-intervention (week 0), and post-intervention (week 13)

Secondary outcomes

  1. Improvement in Psychological Distress

    Self-Report Questionnaire-20 (SRQ-20), measuring non-specific psychological distress. Score range 0-20; Scores \>10 classified as mental distress. A lower score indicates a better outcome.

    Time frame: pre-intervention (week 0), and post-intervention (week 13)

  2. Improvement in Social Performance

    Personal and Social Performance (PSP), measuring social function. A lower score indicates a better outcome.

    Time frame: pre-intervention (week 0), and post-intervention (week 13)

  3. Improvement in Quality of Life

    World Health Organization Quality of Life (WHOQOL), measuring individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns. A higher score indicates a better outcome.

    Time frame: pre-intervention (week 0), and post-intervention (week 13)

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06174714
Lead sponsor
Indonesia University
Responsible party
Kristiana Siste (Dr. dr. Kristiana Siste, SpKJ(K) - Head of Department of Psychiatry, Faculty of Medicine, Indonesia University, Indonesia University) — Principal investigator
First posted
Dec 18, 2023
Start date
Aug 2024 (estimated)
Primary completion
Dec 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Jul 11, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion